Clean Sweep for Teva in VELCADE Patent Action
In a Judgment dated July 18, 2018, Justice Locke allowed Teva’s claim for section 8 damages in relation to its bortezomib product,...Read More
It’s all About Construction
Valeant’s Canadian Patent No. 2,524,300 claims a modified-release bupropion tablet with three parts: a core comprising the active ingredient and various excipients;...Read More